UnitedHealth Group Cash & Equivalents decreased by 98.9% to $305.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 99.1%, from $32.40B to $305.00M. Over 4 years (FY 2020 to FY 2024), Cash & Equivalents shows an upward trend with a 10.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase signals improved liquidity and the ability to fund operations or acquisitions without debt; a decrease may indicate heavy capital expenditure or shareholder returns.
Represents the most liquid assets on the balance sheet, including physical currency and short-term instruments with matu...
Peer tech giants like Alphabet or Apple maintain massive cash reserves to navigate market volatility and fund R&D.
cash_and_equivalents| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.83B | $21.09B | $21.38B | $25.48B | $457.00M | $517.00M | $23.37B | $142.00M | $104.00M | $104.00M | $25.43B | $28.41B | $26.29B | $32.40B | $25.31B | $30.72B | $28.60B | $305.00M |
| QoQ Change | — | +6.3% | +1.4% | +19.2% | -98.2% | +13.1% | >999% | -99.4% | -26.8% | +0.0% | >999% | +11.7% | -7.5% | +23.3% | -21.9% | +21.4% | -6.9% | -98.9% |
| YoY Change | — | — | — | — | -97.7% | -97.5% | +9.3% | -99.4% | -77.2% | -79.9% | +8.8% | >999% | >999% | >999% | -0.5% | +8.1% | +8.8% | -99.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.